License Agreements in the Health Care Equipment & Supplies Industry
628 Contracts & Agreements
- ABIOMED Inc (1 contract)
- ACCURAY INC (2)
- Acrivon Therapeutics, Inc. (2)
- Acutus Medical, Inc. (6)
- ADNEXUS THERAPEUTICS, INC. (5)
- Affinia Therapeutics Inc. (1)
- AIT Therapeutics, Inc. (3)
- ALLIED HEALTHCARE PRODUCTS INC (1)
- ALLOS THERAPEUTICS INC (2)
- Alphatec Holdings, Inc. (17)
- ANTARES PHARMA, INC. (1)
- Apogee Therapeutics, Inc. (5)
- Apollo Endosurgery, Inc. (2)
- APPYEA, INC (2)
- AquaMed Technologies, Inc. (6)
- ARATANA THERAPEUTICS, INC. (12)
- ARGOS THERAPEUTICS INC (9)
- Arno Therapeutics, Inc (3)
- ARYx Therapeutics, Inc. (1)
- AtriCure, Inc. (1)
- Audentes Therapeutics, Inc. (7)
- AV Therapeutics, Inc. (1)
- AxoGen, Inc. (9)
- Axonics Modulation Technologies, Inc. (3)
- BARRIER THERAPEUTICS INC (4)
- Bellerophon Therapeutics, Inc. (1)
- BIOCANCELL THERAPEUTICS INC. (1)
- BIOLASE, INC (2)
- BIOMIMETIC THERAPEUTICS, INC. (1)
- Bionik Laboratories Corp. (3)
- BioSig Technologies, Inc. (3)
- Bioventus Inc. (4)
- Bluejay Diagnostics, Inc. (3)
- Boston Scientific (2)
- BRAIN SCIENTIFIC INC. (1)
- Cadrenal Therapeutics, Inc. (1)
- Cardiovascular Systems Inc (4)
- CARGO Therapeutics, Inc. (10)
- Cascadian Therapeutics, Inc. (5)
- CERUS CORP (1)
- CESCA THERAPEUTICS INC. (4)
- Chelsea Therapeutics International, Ltd. (1)
- CHEMBIO DIAGNOSTICS, INC. (3)
- CHF Solutions, Inc. (2)
- Chromocell Therapeutics Corp (1)
- Co-Diagnostics, Inc. (1)
- Colfax CORP (1)
- Conformis Inc (2)
- Contineum Therapeutics, Inc. (1)
- CORNERSTONE THERAPEUTICS INC (36)
- Coya Therapeutics, Inc. (3)
- CryoLife, Inc. (1)
- CV THERAPEUTICS INC (2)
- Cynapsus Therapeutics Inc. (1)
- Danaher Corp. (1)
- Dare Bioscience, Inc. (16)
- DELCATH SYSTEMS, INC. (3)
- Dimension Therapeutics, Inc. (3)
- Echo Therapeutics, Inc. (7)
- Edwards Lifesciences (2)
- EKSO BIONICS HOLDINGS, INC. (3)
- Elicio Therapeutics, Inc. (1)
- EMBER THERAPEUTICS, INC. - NY (3)
- EMULATE THERAPEUTICS, INC. (5)
- ENCISION INC (1)
- ENDOLOGIX INC (1)
- Envista Holdings Corp (2)
- ERBA Diagnostics, Inc. (1)
- GenMark Diagnostics, Inc. (19)
- GLAUKOS Corp (2)
- Glolex, Inc. (3)
- Glucose Biosensor Systems (Greater China) Holdings, Inc. (7)
- GUIDED THERAPEUTICS INC (1)
- HealthCor Catalio Acquisition Corp. (2)
- Heart Test Laboratories, Inc. (12)
- HELIUS MEDICAL TECHNOLOGIES, INC. (1)
- Heska Corporation (12)
- Holly Brothers Pictures, Inc. (2)
- Hologic (2)
- HYPERION THERAPEUTICS INC (1)
- HYPERTENSION DIAGNOSTICS INC (2)
- Innovative Eyewear Inc (2)
- Inogen, Inc. (2)
- InspireMD, Inc. (4)
- INSULET CORP (7)
- INTARCIA THERAPEUTICS, INC (6)
- INTROGEN THERAPEUTICS INC (3)
- Intuitive Surgical Inc. (1)
- Invea Therapeutics, Inc (2)
- INVIVO THERAPEUTICS HOLDINGS CORP. (3)
- INVO Bioscience, Inc. (1)
- Juno Therapeutics, Inc. (16)
- Kyverna Therapeutics, Inc. (2)
- LeMaitre Vascular, Inc. (3)
- Lexeo Therapeutics, Inc. (10)
- Lirum Therapeutics, Inc. (4)
- Lucid Diagnostics Inc. (2)
- Lucira Health, Inc. (1)
- MABVAX THERAPEUTICS HOLDINGS, INC. (1)
- Masimo (3)
- Medifirst Solutions, Inc. (1)
- MELINTA THERAPEUTICS, INC. (10)
- METABASIS THERAPEUTICS INC (1)
- Mineralys Therapeutics, Inc. (1)
- MINERVA SURGICAL INC (3)
- MISONIX INC (2)
- MRI INTERVENTIONS, INC. (24)
- MYOMO INC (1)
- NanoVibronix, Inc. (1)
- Nemaura Medical Inc. (2)
- Neogen Corporation (1)
- Neon Therapeutics, Inc. (2)
- Neumora Therapeutics, Inc. (8)
- NeuroMetrix, Inc. (2)
- NEUROONE MEDICAL TECHNOLOGIES Corp (4)
- NEVRO CORP (2)
- NOVELION THERAPEUTICS INC. (2)
- OBALON THERAPEUTICS INC (1)
- Ocera Therapeutics, Inc. (6)
- OraSure Technologies, Inc. (1)
- Orexigen Therapeutics, Inc. (4)
- OSIRIS THERAPEUTICS, INC. (2)
- Oxford Immunotec Global PLC (1)
- OxySure Therapeutics, Inc. (4)
- OZOP SURGICAL CORP. (1)
- Peloton Therapeutics, Inc. (1)
- PERNIX THERAPEUTICS HOLDINGS, INC. (1)
- PetVivo Holdings, Inc. (1)
- Precision Therapeutics Inc. (1)
- Primus Therapeutics Inc. (2)
- PRO DEX INC (1)
- PROCEPT BioRobotics Corp (2)
- Pulse Biosciences, Inc. (7)
- Q Therapeutics, Inc. (1)
- QUANTRX BIOMEDICAL CORP (1)
- REMEDENT, INC. (6)
- REPROS THERAPEUTICS INC. (1)
- ReShape Lifesciences Inc. (6)
- Restoration Robotics, Inc. (6)
- RETRACTABLE TECHNOLOGIES INC (1)
- ReWalk Robotics Ltd. (2)
- ROCKWELL MEDICAL, INC. (3)
- RTI Surgical Holdings, Inc. (1)
- RTI SURGICAL, INC. (3)
- RxSight, Inc. (3)
- Sandbridge Acquisition Corp (1)
- SANUWAVE Health, Inc. (1)
- SECOND SIGHT MEDICAL PRODUCTS INC (2)
- Silk Road Medical Inc (5)
- Sintx Technologies, Inc. (4)
- Spark Therapeutics, Inc. (3)
- STEMLINE THERAPEUTICS INC (9)
- STRATA Skin Sciences, Inc. (1)
- Surmodics, Inc. (1)
- Synvista Therapeutics, Inc. (3)
- TACTILE SYSTEMS TECHNOLOGY INC (1)
- Talon Therapeutics, Inc. (6)
- TANDEM DIABETES CARE INC (1)
- Targanta Therapeutics Corp. (1)
- TearLab Corp (8)
- TELA Bio, Inc. (6)
- The Cooper Companies (1)
- Tobira Therapeutics, Inc. (8)
- TRANSENTERIX INC. (2)
- VERMILLION, INC. (3)
- Vidara Therapeutics International Ltd (6)
- ViewRay, Inc. (12)
- Vividion Therapeutics, Inc. (1)
- VOLITIONRX LTD (4)
- WOUND MANAGEMENT TECHNOLOGIES, INC. (5)
- Zander Therapeutics, Inc (1)
- Amendment No. 3, dated February 11, 2024, to the First License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University (as amended by... (Lexeo Therapeutics, Inc., Filed With SEC on April 9, 2024)
- License Agreement between Aspira Womens Health Inc. and Dana-Farber Cancer Institute, Inc. effective March 20, 2023 (VERMILLION, INC., Filed With SEC on April 1, 2024)
- Addendum to the Second Amended and Restated License, Product Development and Supply Umbrella Agreement, dated August 13, 2020, by and between the Company and Aroa Biosurgery Ltd (TELA Bio, Inc., Filed With SEC on March 22, 2024)
- Development and License Agreement by and among Coya Therapeutics, Inc., Dr. Reddy's Laboratories SA, and Dr. Reddy's Laboratories Ltd., dated December 5, 2023 (Coya Therapeutics, Inc., Filed With SEC on March 19, 2024)
- License Agreement, dated February 3, 2023, by and between the Registrant and Janssen Pharmaceutica NV (Contineum Therapeutics, Inc., Filed With SEC on March 15, 2024)
- Third Amendment to the License Agreement between Lirum Therapeutics, Inc. and IGF Oncology, LLC (Lirum Therapeutics, Inc., Filed With SEC on March 11, 2024)
- Second Amendment to the License Agreement between Lirum Therapeutics, Inc. and IGF Oncology, LLC (Lirum Therapeutics, Inc., Filed With SEC on March 11, 2024)
- First Amendment to the License Agreement between Lirum Therapeutics, Inc. and IGF Oncology (Lirum Therapeutics, Inc., Filed With SEC on March 11, 2024)
- License Agreement between Lirum Therapeutics, Inc. and IGF Oncology, LLC dated January 12 (Lirum Therapeutics, Inc., Filed With SEC on March 11, 2024)
- Patent License Agreement (License Number L-159-2021-0), dated May 27, 2021, between Kyverna Therapeutics, Inc. and the National Institutes of Health (Kyverna Therapeutics, Inc., Filed With SEC on January 16, 2024)
- Patent License Agreement (License Number L-158-2021-0), dated May 20, 2021, between Kyverna Therapeutics, Inc. and the National Institutes of Health (Kyverna Therapeutics, Inc., Filed With SEC on January 16, 2024)
- Benuvia License Agreement (Chromocell Therapeutics Corp, Filed With SEC on January 16, 2024)
- First Amendment to License Agreement by and between Organon International GmbH and Dar Bioscience, Inc., entered into as of July 4, 2023 (Dare Bioscience, Inc., Filed With SEC on November 9, 2023)
- Patent License Agreement, dated February 24, 2023, by and between the Registrant and the National Cancer Institute (CARGO Therapeutics, Inc., Filed With SEC on November 6, 2023)
- Patent License Agreement, dated March 16, 2022, by and between the Registrant and the National Cancer Institute (CARGO Therapeutics, Inc., Filed With SEC on November 6, 2023)
- License and Supply Agreement, dated June 24, 2022, by and between the Registrant and Oxford Biomedica (UK) Limited (CARGO Therapeutics, Inc., Filed With SEC on November 6, 2023)
- Amendment No. 1 to Exclusive License Agreement effective August 1, 2022, by and between the Registrant and the Board of Trustees of the Leland Stanford Junior University (CARGO Therapeutics, Inc., Filed With SEC on November 6, 2023)
- Exclusive License Agreement effective August 1, 2022, by and between the Registrant and the Board of Trustees of the Leland Stanford Junior University (CARGO Therapeutics, Inc., Filed With SEC on November 6, 2023)
- License and Supply Agreement, dated June 24, 2022, by and between the Registrant and Oxford Biomedica (UK) Limited (CARGO Therapeutics, Inc., Filed With SEC on November 1, 2023)
- Amended and Restated License Agreement, entered into on October 23, 2023, by and between Bluejay Diagnostics, Inc. and Toray Industries, Inc (Bluejay Diagnostics, Inc., Filed With SEC on October 26, 2023)
- Patent License Agreement, dated February 24, 2023, by and between the Registrant and the National Cancer Institute (CARGO Therapeutics, Inc., Filed With SEC on October 20, 2023)
- Patent License Agreement, dated March 16, 2022, by and between the Registrant and the National Cancer Institute (CARGO Therapeutics, Inc., Filed With SEC on October 20, 2023)
- Amendment No. 1 to Exclusive License Agreement effective August 1, 2022, by and between the Registrant and the Board of Trustees of the Leland Stanford Junior University (CARGO Therapeutics, Inc., Filed With SEC on October 20, 2023)
- Exclusive License Agreement effective August 1, 2022, by and between the Registrant and the Board of Trustees of the Leland Stanford Junior University (CARGO Therapeutics, Inc., Filed With SEC on October 20, 2023)
- License Agreement, by and between the Registrant and InveniAI LLC, dated October 4, 2023 (Invea Therapeutics, Inc, Filed With SEC on October 20, 2023)
- License Agreement, by and between InveniAI LLC and Daiichi Sankyo Company, Limited, dated September 1, 2021 (Invea Therapeutics, Inc, Filed With SEC on October 20, 2023)
- DBS License Agreement, dated as of September 29, 2023, by and between Veralto Corporation and Danaher Corporation (Danaher Corp., Filed With SEC on October 2, 2023)
- License Agreement, dated January 19, 2021, between Adverum Biotechnologies, Inc. and LEXEO Therapeutics, Inc., as amended by the First Amendment, dated February 28, 2022 (Lexeo Therapeutics, Inc., Filed With SEC on September 29, 2023)
- Amendment No. 2, dated September 28, 2022, to the First License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University (as amended by... (Lexeo Therapeutics, Inc., Filed With SEC on September 29, 2023)
- Amendment No. 1, dated July 4, 2022, to the First License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University and Amendment No. 2, dated... (Lexeo Therapeutics, Inc., Filed With SEC on September 29, 2023)
- Amendment No. 1, dated January 13, 2022, to the Second License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University (Lexeo Therapeutics, Inc., Filed With SEC on September 29, 2023)
- Second License Agreement, dated May 28, 2020, between LEXEO Therapeutics, LLC and Cornell University (Lexeo Therapeutics, Inc., Filed With SEC on September 29, 2023)
- First License Agreement, dated May 28, 2020, between LEXEO Therapeutics, LLC and Cornell University (Lexeo Therapeutics, Inc., Filed With SEC on September 29, 2023)
- License Agreement, dated August 6, 2020, by and between Stelios Therapeutics, Inc. and the Regents of the University of California (Lexeo Therapeutics, Inc., Filed With SEC on September 29, 2023)
- License Agreement, dated April 23, 2020, by and between Stelios Therapeutics, Inc. (as successor-in-interest to ARVC Therapeutics, Inc.) and the Regents of the University of... (Lexeo Therapeutics, Inc., Filed With SEC on September 29, 2023)
- License Agreement, dated October 4, 2021, by and between LEXEO Therapeutics, Inc. and the Regents of the University of California (Lexeo Therapeutics, Inc., Filed With SEC on September 29, 2023)
- Exclusive License Agreement, dated September 19, 2023, by and between ReShape Lifesciences Inc. and Biorad Medysis Pvt. Ltd (OBALON THERAPEUTICS INC, Filed With SEC on September 22, 2023)
- License: Electrocardiogram Deep Learning Interpretability Toolbox (Heart Test Laboratories, Inc., Filed With SEC on September 21, 2023)
- License: Diagnosis of STEMI using a model derived from a foundational vision transformer (HeartBEiT) (Heart Test Laboratories, Inc., Filed With SEC on September 21, 2023)
- License: Diagnosis of Hypertrophic Cardiomyopathy using a model derived from a foundational vision transformer (HeartBEiT) (Heart Test Laboratories, Inc., Filed With SEC on September 21, 2023)